Search icon

MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) - Florida Company Profile

Company claim

Is this your business?

Get access!

Company Details

Entity Name: MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)
Jurisdiction: FLORIDA
Filing Type: Domestic Non-Profit
Status: Active

The business entity is active. This status indicates that the business is currently operating and compliant with state regulations, suggesting a lower risk profile for lenders and potentially better creditworthiness.

Date Filed: 12 Jun 1995 (30 years ago)
Last Event: AMENDMENT
Event Date Filed: 22 Mar 2010 (15 years ago)
Document Number: N95000002858
FEI/EIN Number 593337028

Federal Employer Identification (FEI) Number assigned by the IRS.

Address: 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
Mail Address: 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
ZIP code: 32224
County: Duval
Place of Formation: FLORIDA

Key Officers & Management

Name Role Address
JOHNSON MARGARET MDr. Director 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
MCLAUGHLIN SARAH ADr. Director 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
Thielen Kent R Chief Executive Officer 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
BUSKIRK TIMOTHY Agent 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
Quinones-Hinojosa Alfredo Dr. Director 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
Dronca Roxana S Director 4500 SAN PABLO RD., JACKSONVILLE, FL, 32224
Bruce Charles MMD Director 4500 SAN PABLO RD, JACKSONVILLE, FL, 32224

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
GKPBCFV1QMM3
CAGE Code:
01JF4
UEI Expiration Date:
2025-08-01

Business Information

Activation Date:
2024-08-05
Initial Registration Date:
2001-02-09

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
01JF4
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-08-05
CAGE Expiration:
2029-08-05
SAM Expiration:
2025-08-01

Contact Information

POC:
PAUL HAINES

Immediate Level Owner

Vendor Certified:
2024-08-05
CAGE number:
5A021
Company Name:
MAYO CLINIC

Fictitious Names

Registration Number Fictitious Name Status Filed Date Expiration Date Cancellation Date Mailing Address
G25000029497 DUAN FAMILY BUILDING ACTIVE 2025-02-27 2030-12-31 - 4500 SAN PABLO ROAD S, JACKSONVILLE, FL, 32224
G22000127680 MAYO CLINIC JACKSONVILLE ELECTRON MICROSCOPY LAB ACTIVE 2022-10-12 2027-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G22000085397 MAYO CLINIC JACKSONVILLE MOBILE POINT OF CARE LAB ACTIVE 2022-07-19 2027-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G20000100121 MAYO CLINIC SCHOOL OF HEALTH SCIENCES ACTIVE 2020-08-07 2025-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G20000064510 MAYO CLINIC IN JACKSONVILLE ACTIVE 2020-06-09 2025-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G19000114975 MAYO CLINIC SPORTS MEDICINE ACTIVE 2019-10-23 2029-12-31 - C/O MAYO CLINIC JACKSONVILLE, 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G19000058722 LIFE SCIENCES INCUBATOR ACTIVE 2019-05-16 2029-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G19000053657 MAYO CLINIC COUMADIN CLINIC LABORATORY ACTIVE 2019-05-01 2029-12-31 - MAYO CLINIC JACKSONVILLE, 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G19000053218 MAYO CLINIC JACKSONVILLE MEDICAL TRANSPORT ACTIVE 2019-04-30 2029-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224
G19000028404 MAYO CLINIC LOCATED AT GATE PARKWAY ACTIVE 2019-02-28 2029-12-31 - 4500 SAN PABLO ROAD, JACKSONVILLE, FL, 32224

Events

Event Type Filed Date Value Description
REGISTERED AGENT NAME CHANGED 2024-01-09 BUSKIRK, TIMOTHY -
REGISTERED AGENT ADDRESS CHANGED 2019-01-14 4500 SAN PABLO RD., JACKSONVILLE, FL 32224 -
AMENDMENT 2010-03-22 - -
MERGER 2006-06-30 - CORPORATION WAS A MERGER RESULT. TOTAL NUMBER OF QUALIFIED CORPORATION(S) INVOLVED WAS 1. MERGER NUMBER 700000058117
AMENDMENT 1999-12-30 - -
NAME CHANGE AMENDMENT 1996-12-20 MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) -

Documents

Name Date
ANNUAL REPORT 2024-01-09
ANNUAL REPORT 2023-02-01
ANNUAL REPORT 2022-01-13
ANNUAL REPORT 2021-01-28
ANNUAL REPORT 2020-01-17
ANNUAL REPORT 2019-04-24
Reg. Agent Change 2019-01-14
ANNUAL REPORT 2018-03-27
ANNUAL REPORT 2017-03-06
ANNUAL REPORT 2016-02-24

USAspending Awards / Contracts

Procurement Instrument Identifier:
36C24925P0108
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
51105.00
Base And Exercised Options Value:
51105.00
Base And All Options Value:
51105.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2024-10-30
Description:
RATIFICATION OF AN UNAUTHORIZED COMMITMENT
Naics Code:
621111: OFFICES OF PHYSICIANS (EXCEPT MENTAL HEALTH SPECIALISTS)
Product Or Service Code:
Q508: HEMATOLOGY & ONCOLOGY
Procurement Instrument Identifier:
36C26223C0234
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
55414.00
Base And Exercised Options Value:
55414.00
Base And All Options Value:
55414.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2023-08-01
Description:
HUMANIZATION AND BINDING AFFINITY TESTING
Naics Code:
541720: RESEARCH AND DEVELOPMENT IN THE SOCIAL SCIENCES AND HUMANITIES
Product Or Service Code:
AN42: HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
Procurement Instrument Identifier:
75N91018P00618
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
36000.00
Base And Exercised Options Value:
36000.00
Base And All Options Value:
36000.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2018-09-13
Description:
SERVICES TO OBTAIN DNA SAMPLES AND PATIENT DATA FOR 1,100 RENAL CELL CARCINOMA CASES (RCC) FOR INCLUSION IN A GENOME-WIDE ASSOCIATION STUDY (GWAS)
Naics Code:
541380: TESTING LABORATORIES
Product Or Service Code:
R499: SUPPORT- PROFESSIONAL: OTHER

USAspending Awards / Financial Assistance

Date:
2025-04-03
Awarding Agency Name:
Department of Defense
Transaction Description:
RESOLVING THE CRITICAL ROLE OF PINK1 EXPRESSION AND ACTIVITY IN PARKINSON'S DISEASE PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTION
Obligated Amount:
813085.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2025-04-03
Awarding Agency Name:
Department of Defense
Transaction Description:
RESOLVING THE CRITICAL ROLE OF PINK1 EXPRESSION AND ACTIVITY IN PARKINSON'S DISEASE PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTION
Obligated Amount:
1186914.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2025-04-08
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
STANDARDIZING AND HARMONIZING BEHAVIORAL AND SOCIAL SCIENCE RESEARCH FACTORS IN ALZHEIMER'S DISEASE THROUGH ONTOLOGY-BASED APPROACHES - ABSTRACT BEHAVIORAL AND SOCIAL SCIENCE RESEARCH (BSSR) IS INSTRUMENTAL IN COMPREHENDING ALZHEIMER'S DISEASE AND RELATED DEMENTIA (ADRD) AND ITS FAR-REACHING IMPLICATIONS FOR INDIVIDUALS, FAMILIES, AND COMMUNITIES. BSSR INVESTIGATES HOW BEHAVIORAL AND SOCIAL DETERMINANTS, ENCOMPASSING FACTORS LIKE PHYSICAL ACTIVITY, COGNITIVE ENGAGEMENT, DIET, AND SOCIAL INTERACTIONS, INFLUENCE THE RISK OF DEVELOPING AD. THIS EXPLORATION AIMS TO UNCOVER NON-PHARMACOLOGICAL INTERVENTIONS THAT CAN MANAGE SYMPTOMS AND ENHANCE THE WELL-BEING OF INDIVIDUALS WITH AD/ADRD, INCLUDING COGNITIVE STIMULATION PROGRAMS, BEHAVIORAL THERAPIES, SOCIAL ENGAGEMENT INITIATIVES, AND CAREGIVER TRAINING. MOREOVER, BSSR DELVES INTO THE SOCIAL, CULTURAL, AND ENVIRONMENTAL ELEMENTS CONTRIBUTING TO HEALTH DISPARITIES, INFORMING TAILORED INTERVENTIONS AND POLICIES FOR VARIOUS POPULATIONS, ESPECIALLY UNDERSERVED AND MINORITY COMMUNITIES. COLLECTIVELY, THIS RESEARCH ENRICHES OUR UNDERSTANDING OF ADRD AND GUIDES THE DEVELOPMENT OF INTERVENTIONS, SUPPORT SYSTEMS, AND POLICIES TO ENHANCE THE LIVES OF THOSE AFFECTED BY THE DISEASE. YET, THERE ARE CHALLENGES IMPEDING THE INTEGRATION OF ADRD-RELATED BSSR DATA. A CRITICAL ISSUE IS THE ABSENCE OF FORMAL REPRESENTATIONS FOR BSSR DATA AND LIMITED TOOLS TO LINK COMPREHENSIVE BSSR INFORMATION FROM DIVERSE SOURCES. THIS HAMPERS THE HOLISTIC CONSIDERATION OF BSSR FACTORS IN AD-RELATED RESEARCH, UNDERMINING EVIDENCE-BASED CARE AND SUPPORT. IN RESPONSE TO PAR-23-182, WE PROPOSE PIONEERING ONTOLOGY-BASED APPROACHES TO FORMALLY REPRESENT ADRD-RELATED BSSR FACTORS IN A STANDARDIZED MANNER. WE WILL DEVELOP NATURAL LANGUAGE PROCESSING (NLP) METHODS TO EXTRACT AND NORMALIZE BSSR DATA FROM ELECTRONIC HEALTH RECORDS (EHRS) AND LITERATURE. OUR PROJECT AIMS TO INTEGRATE STRUCTURED AND UNSTRUCTURED DATA ACROSS VARIOUS RESEARCH SILOS, CULMINATING IN A COMPREHENSIVE AND NORMALIZED KNOWLEDGE GRAPH INCORPORATING BSSR FACTORS FOR ADRD COHORTS. MORE SPECIFICALLY, IN AIM 1, WE WILL DEVELOP THE BEHAVIORAL SOCIAL DATA AND KNOWLEDGE ONTOLOGY FOR ADRD (BSO-AD) TO STANDARDIZE BSSR FACTORS. WE WILL ALSO ASSESS THE BSO-AD FOR CORRECTNESS AND SUITABILITY, REFINING IT BASED ON EVALUATION SCORES. AIM 2 EMPLOYS NLP TECHNOLOGIES, INCLUDING STATE-OF-THE-ART LARGE LANGUAGE MODELS, TO EXTRACT AND NORMALIZE BSSR-RELATED INFORMATION FROM CLINICAL NOTES AND LITERATURE. THIS NLP SYSTEM WILL ENSURE SEMANTIC INTEROPERABILITY AND CONSISTENCY IN ENTITY RECOGNITION AND NORMALIZATION. IN AIM 3, WE WILL CREATE A KNOWLEDGE GRAPH (KG) TO INTEGRATE ANNOTATED BSSR FACTORS FROM STRUCTURED AND UNSTRUCTURED SOURCES, SUPPORTING ADRD-RELATED RESEARCH AND APPLICATIONS. WE WILL EVALUATE THE ONTOLOGY AND KG THROUGH DEMONSTRATION STUDIES AND DISSEMINATE THESE RESOURCES TO THE RESEARCH COMMUNITY, PROMOTING COLLABORATIVE RESEARCH EFFORTS. IN SUMMARY, OUR PROJECT AIMS TO BRIDGE THE GAP IN ADRD-RELATED BSSR DATA INTEGRATION BY STANDARDIZING REPRESENTATION, ENABLING EFFICIENT EXTRACTION, AND FOSTERING COLLABORATION WITHIN THE RESEARCH COMMUNITY. THIS ENDEAVOR WILL ADVANCE OUR UNDERSTANDING OF ADRD AND CONTRIBUTE TO EVIDENCE-BASED CARE AND SUPPORT FOR AFFECTED INDIVIDUALS AND THEIR COMMUNITIES.
Obligated Amount:
801130.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2025-04-16
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DECIPHERING PANCREATITIS MICROENVIRONMENT THROUGH INTRAVITAL IMAGING - PROJECT SUMMARY ACUTE PANCREATITIS (AP) IS A PREVALENT GASTROINTESTINAL CONDITION THAT LEADS TO A SIGNIFICANT NUMBER OF HOSPITALIZATIONS AND HIGH HEALTHCARE COSTS. WITH NO EFFECTIVE THERAPY CURRENTLY AVAILABLE, THERE IS AN URGENT NEED FOR RESEARCH TO DEVELOP SUCCESSFUL TREATMENTS. THIS PROPOSAL AIMS TO INVESTIGATE THE ROLES OF TRYPSIN AND COAGULATION IN THE DEVELOPMENT OF ACUTE PANCREATITIS AND EXPLORE THE HYPOTHESIS THAT THROMBIN PLAYS A CRUCIAL ROLE IN THE DISEASE. PREVIOUS STUDIES HAVE SHOWN THAT THROMBIN, A DUAL THROMBIN AND TRYPSIN INHIBITOR, HAS SUPERIOR EFFECTS IN PREVENTING AND TREATING ACUTE PANCREATITIS COMPARED TO SELECTIVE TRYPSIN INHIBITORS. THIS SUGGESTS THAT ANTI- TRYPSIN AND ANTI-COAGULATION MECHANISMS WORK TOGETHER TO COMBAT THE DISEASE. TO INVESTIGATE THIS FURTHER, GENETIC APPROACHES WILL BE USED, INCLUDING A NEWLY ENGINEERED TRYPSIN KNOCKOUT MOUSE MODEL (T2457) AND A CONDITIONAL THROMBIN KNOCKOUT MOUSE MODEL. THE RESEARCH WILL FOCUS ON DISSECTING THE ROLES OF TRYPSIN AND COAGULATION IN ACUTE PANCREATITIS INITIATION AND PROGRESSION. ADDITIONALLY, THE IMPACT OF THROMBIN ON THE PANCREATIC MICROENVIRONMENT WILL BE EXAMINED USING A MULTI-PHOTON INTRAVITAL IMAGING SYSTEM. THROMBIN INHIBITORS, PAR RECEPTOR INHIBITORS, AND PAR1 KNOCKOUT MICE WILL BE UTILIZED TO GAIN A BETTER UNDERSTANDING OF THE COAGULATION PATHWAY'S INFLUENCE ON ACUTE PANCREATITIS. IN THE FINAL AIM, THE PROJECT WILL CONCENTRATE ON ENHANCING DRUG DELIVERY TO THE INFLAMED PANCREAS, ADDRESSING THE ISSUE OF LOW DRUG CONCENTRATIONS IN THE AFFECTED TISSUE. DABIGATRAN WILL BE USED AS A MODEL DRUG, AND PROOF-OF-PRINCIPLE STUDIES WILL BE CONDUCTED TO DEVELOP PANCREATITIS-SPECIFIC DRUGS THAT IMPROVE DRUG DELIVERY. AN INTRAVENOUS FORMULATION OF DABIGATRAN WILL BE FORMULATED AND TESTED FOR THERAPEUTIC EFFICACY, ALONG WITH TWO PRODRUGS DESIGNED TO ACTIVATE LOCALLY IN THE PANCREAS. THE COMPLETION OF THIS PROJECT WILL SIGNIFICANTLY ADVANCE THE UNDERSTANDING OF ACUTE PANCREATITIS PATHOPHYSIOLOGY AND CONTRIBUTE TO THE DEVELOPMENT OF TARGETED THERAPIES. THE KNOWLEDGE GAINED WILL PROVIDE A SOLID FOUNDATION FOR FUTURE CLINICAL TRIALS AIMED AT PREVENTING AND TREATING ACUTE PANCREATITIS. ULTIMATELY, THIS RESEARCH HAS THE POTENTIAL TO IMPACT PATIENT OUTCOMES AND IMPROVE THE MANAGEMENT OF THIS CHALLENGING CONDITION.
Obligated Amount:
1157318.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2025-04-15
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
PROTEIN KINASE D1 AS A SWITCH FROM ACUTE TO CHRONIC PANCREATITIS - PROJECT SUMMARY/ABSTRACT ACUTE PANCREATITIS, IF IT DOESN’T RESOLVE, CAN FURTHER DEVELOP INTO A CHRONIC CONDITION. RESULTING CHRONIC PANCREATITIS IS CHARACTERIZED BY PRESENCE OF INFLAMMATORY MACROPHAGES, FIBROSIS, AND LOSS OF ACINAR CELLS. MOREOVER, IT REPRESENTS A RISK FACTOR FOR PANCREATIC CANCER. THE CELLULAR AND MOLECULAR MECHANISMS THAT MEDIATE THE TRANSITION FROM ACUTE TO CHRONIC PANCREATITIS ARE ILL-DEFINED, AND EFFICIENT THERAPEUTIC TREATMENT METHODS FOR CHRONIC PANCREATITIS ARE LACKING. IN THIS PROPOSAL, IT IS OUR HYPOTHESIS THAT PROTEIN KINASE D1 PRIMES ACINAR CELLS TO PRODUCE FACTORS THAT PREVENT ACUTE PANCREATITIS FROM RESOLVING AND GENERATES A CHRONIC CONDITION. WE FURTHER HYPOTHESIZE THAT THE RESULTING CHRONIC PANCREATITIS CAN BE TARGETED WITH PKD INHIBITORS. TO TEST THIS WE WILL: DETERMINE HOW PKD1 EXPRESSION IN ACINAR CELLS CAN GENERATE AN ENVIRONMENT THAT IS FAVORABLE FOR DEVELOPING CHRONIC PANCREATITIS (SPECIFIC AIM 1); AND UTILIZE OUR ACINAR CELL- TARGETED ANIMAL MODELS TO DETERMINE THE EFFECTS OF PKD1 ON DEVELOPMENT AND RESOLUTION OF CHRONIC PANCREATITIS (SPECIFIC AIM 2). SUCCESSFUL COMPLETION OF THIS PROJECT WILL DEFINE THE ROLE OF ACTIVATED PKD1 IN ALTERING PANCREATIC ACINAR CELLS IN A WAY THAT THEY CAN FACILITATE THE TRANSITION OF ACUTE PANCREATITIS TO A CHRONIC STATE. WE WILL DEFINE HOW THESE MOLECULAR CHANGES AFFECT CELLS IN THE PANCREATIC ENVIRONMENT AND THE IMMUNE LANDSCAPE IN THE PANCREAS. EVENTUALLY, WE WILL DETERMINE IF INHIBITION OF PKD1 IN VIVO CAN RESOLVE CHRONIC PANCREATITIS. THIS WILL LAY THE GROUNDWORK OF DEVELOPING TARGETED TREATMENT STRATEGIES FOR PANCREATITIS BASED ON INHIBITION OF PKD1 OR DOWNSTREAM SIGNALING EVENTS.
Obligated Amount:
680776.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Reviews Leave a review

This company hasn't received any reviews.

Date of last update: 03 Jun 2025

Sources: Florida Department of State